Modulation of Apoptosis by Natural Products for Cancer Therapy

Abstract

Natural products can exhibit many beneficial effects on human health. As far as cancer is concerned, naturally occurring compounds have been reported to prevent tumorigenesis and also to suppress the growth of established tumors. As cancer cells have evolved multiple mechanisms to resist the induction of programmed cell death (apoptosis), the modulation of apoptosis signaling pathways by natural compounds has been demonstrated to constitute a key event in these antitumor activities. This review presents some examples of how apoptosis pathways are targeted by selected naturally occurring agents and how these events can be exploited for cancer therapy.

Key words

natural products - apoptosis - cancer therapy

References

• 1 Nobili S, Lippi D, Witort E, Donnini M, Bausi L, Mini E, Capaccioli S. Natural compounds for cancer treatment and prevention.  Pharmacol Res. 2009;  59 365-378
• 2 Lockshin R A, Zakeri Z. Cell death in health and disease.  J Cell Mol Med. 2007;  11 1214-1224
• 3 Fulda S. Tumor resistance to apoptosis.  Int J Cancer. 2009;  124 511-515
• 4 Hanahan D, Weinberg R A. The hallmarks of cancer.  Cell. 2000;  100 57-70
• 5 Degterev A, Boyce M, Yuan J. A decade of caspases.  Oncogene. 2003;  22 8543-8567
• 6 Fulda S, Debatin K M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy.  Oncogene. 2006;  25 4798-4811
• 7 Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer.  Cytokine Growth Factor Rev. 2008;  19 325-331
• 8 Walczak H, Krammer P H. The CD95 (APO-1/Fas) and the TRAIL (APO-2 L) apoptosis systems.  Exp Cell Res. 2000;  256 58-66
• 9 Adams J M, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy.  Oncogene. 2007;  26 1324-1337
• 10 Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death.  Physiol Rev. 2007;  87 99-163
• 11 Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G, Vandenabeele P. Toxic proteins released from mitochondria in cell death.  Oncogene. 2004;  23 2861-2874
• 12 LaCasse E C, Mahoney D J, Cheung H H, Plenchette S, Baird S, Korneluk R G. IAP-targeted therapies for cancer.  Oncogene. 2008;  27 6252-6275
• 13 Okada H, Mak T W. Pathways of apoptotic and non-apoptotic death in tumour cells.  Nat Rev Cancer. 2004;  4 592-603
• 14 Fulda S, Scaffidi C, Susin S A, Krammer P H, Kroemer G, Peter M E, Debatin K M. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid.  J Biol Chem. 1998;  273 33942-33948
• 15 Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, Nunez G, Krammer P H, Peter M E, Debatin K M. Betulinic acid triggers CD95 (APO-1/Fas)- and p 53-independent apoptosis via activation of caspases in neuroectodermal tumors.  Cancer Res. 1997;  57 4956-4964
• 16 Liby K T, Yore M M, Sporn M B. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer.  Nat Rev Cancer. 2007;  7 357-369
• 17 Fulda S, Susin S A, Kroemer G, Debatin K M. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells.  Cancer Res. 1998;  58 4453-4460
• 18 Andre N, Carre M, Brasseur G, Pourroy B, Kovacic H, Briand C, Braguer D. Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells.  FEBS Lett. 2002;  532 256-260
• 19 Zuco V, Supino R, Righetti S C, Cleris L, Marchesi E, Gambacorti-Passerini C, Formelli F. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells.  Cancer Lett. 2002;  175 17-25
• 20 Salti G I, Kichina J V, Das Gupta T K, Uddin S, Bratescu L, Pezzuto J M, Mehta R G, Constantinou A I. Betulinic acid reduces ultraviolet-C-induced DNA breakage in congenital melanocytic naeval cells: evidence for a potential role as a chemopreventive agent.  Melanoma Res. 2001;  11 99-104
• 21 Meng R D, El-Deiry W S. p 53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma.  Exp Cell Res. 2001;  262 154-169
• 22 Fulda S, Debatin K M. Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors.  Med Pediatr Oncol. 2000;  35 616-618
• 23 Wick W, Grimmel C, Wagenknecht B, Dichgans J, Weller M. Betulinic acid-induced apoptosis in glioma cells: a sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing.  J Pharmacol Exp Ther. 1999;  289 1306-1312
• 24 Selzer E, Pimentel E, Wacheck V, Schlegel W, Pehamberger H, Jansen B, Kodym R. Effects of betulinic acid alone and in combination with irradiation in human melanoma cells.  J Invest Dermatol. 2000;  114 935-940
• 25 Gledhill J R, Montgomery M G, Leslie A G, Walker J E. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols.  Proc Natl Acad Sci USA. 2007;  104 13632-13637
• 26 Fulda S, Debatin K M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol.  Cancer Res. 2004;  64 337-346
• 27 Jazirehi A R, Bonavida B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis.  Mol Cancer Ther. 2004;  3 71-84
• 28 She Q-B, Huang C, Zhang Y, Dong Z. Involvement of c-jun NH(2)-terminal kinases in resveratrol-induced activation of p 53 and apoptosis.  Mol Carcinogen. 2002;  33 244-250
• 29 Kaneuchi M, Sasaki M, Tanaka Y, Yamamoto R, Sakuragi N, Dahiya R. Resveratrol suppresses growth of Ishikawa cells through down-regulation of EGF.  Int J Oncol. 2003;  23 1167-1172
• 30 Pozo-Guisado E, Lorenzo-Benayas M J, Fernandez-Salguero P M. Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation.  Int J Cancer. 2004;  109 167-173
• 31 Jiang H, Shang X, Wu H, Gautam S C, Al-Holou S, Li C, Kuo J, Zhang L, Chopp M. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells.  J Exp Ther Oncol. 2009;  8 25-33
• 32 Shaw R J, Cantley L C. Ras, PI(3)K and mTOR signalling controls tumour cell growth.  Nature. 2006;  441 424-430
• 33 Biasutto L, Mattarei A, Marotta E, Bradaschia A, Sassi N, Garbisa S, Zoratti M, Paradisi C. Development of mitochondria-targeted derivatives of resveratrol.  Bioorg Med Chem Lett. 2008;  18 5594-5597
• 34 Constantinou C, Papas A, Constantinou A I. Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs.  Int J Cancer. 2008;  123 739-752
• 35 Dong L F, Low P, Dyason J C, Wang X F, Prochazka L, Witting P K, Freeman R, Swettenham E, Valis K, Liu J, Zobalova R, Turanek J, Spitz D R, Domann F E, Scheffler I E, Ralph S J, Neuzil J. Alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II.  Oncogene. 2008;  27 4324-4335
• 36 Dong L F, Swettenham E, Eliasson J, Wang X F, Gold M, Medunic Y, Stantic M, Low P, Prochazka L, Witting P K, Turanek J, Akporiaye E T, Ralph S J, Neuzil J. Vitamin E analogues inhibit angiogenesis by selective induction of apoptosis in proliferating endothelial cells: the role of oxidative stress.  Cancer Res. 2007;  67 11906-11913
• 37 Jia L, Yu W, Wang P, Sanders B G, Kline K. In vivo and in vitro studies of anticancer actions of alpha-TEA for human prostate cancer cells.  Prostate. 2008;  68 849-860
• 38 Hahn T, Szabo L, Gold M, Ramanathapuram L, Hurley L H, Akporiaye E T. Dietary administration of the proapoptotic vitamin E analogue alpha-tocopheryloxyacetic acid inhibits metastatic murine breast cancer.  Cancer Res. 2006;  66 9374-9378
• 39 Lawson K A, Anderson K, Simmons-Menchaca M, Atkinson J, Sun L, Sanders B G, Kline K. Comparison of vitamin E derivatives alpha-TEA and VES in reduction of mouse mammary tumor burden and metastasis.  Exp Biol Med (Maywood). 2004;  229 954-963
• 40 Neuzil J, Weber T, Schroder A, Lu M, Ostermann G, Gellert N, Mayne G C, Olejnicka B, Negre-Salvayre A, Sticha M, Coffey R J, Weber C. Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements.  FASEB J. 2001;  15 403-415
• 41 Lynn A, Jones L. Gossypol and some other terpenoids, flavonoids, and phenols that affect quality of cottonseed protein.  J Am Oil Chem Soc. 1979;  56 727-730
• 42 Azmi A S, Mohammad R M. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.  J Cell Physiol. 2009;  218 13-21
• 43 Kitada S, Kress C L, Krajewska M, Jia L, Pellecchia M, Reed J C. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048).  Blood. 2008;  111 3211-3219
• 44 Liu G, Kelly W K, Wilding G, Leopold L, Brill K, Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer.  Clin Cancer Res. 2009;  15 3172-3176
• 45 Marchetti P, Zamzami N, Joseph B, Schraen-Maschke S, Mereau-Richard C, Costantini P, Metivier D, Susin S A, Kroemer G, Formstecher P. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus.  Cancer Res. 1999;  59 6257-6266
• 46 Belzacq A S, El Hamel C, Vieira H L, Cohen I, Haouzi D, Metivier D, Marchetti P, Brenner C, Kroemer G. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437.  Oncogene. 2001;  20 7579-7587
• 47 Notario B, Zamora M, Vinas O, Mampel T. All-trans-retinoic acid binds to and inhibits adenine nucleotide translocase and induces mitochondrial permeability transition.  Mol Pharmacol. 2003;  63 224-231
• 48 Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao P J, Achanta G, Arlinghaus R B, Liu J, Huang P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate.  Cancer Cell. 2006;  10 241-252
• 49 Xiao D, Lew K L, Zeng Y, Xiao H, Marynowski S W, Dhir R, Singh S V. Phenethyl isothiocyanate-induced apoptosis in PC-3 human prostate cancer cells is mediated by reactive oxygen species-dependent disruption of the mitochondrial membrane potential.  Carcinogenesis. 2006;  27 2223-2234
• 50 Huang P, Feng L, Oldham E A, Keating M J, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells.  Nature. 2000;  407 390-395
• 51 Juarez J C, Manuia M, Burnett M E, Betancourt O, Boivin B, Shaw D E, Tonks N K, Mazar A P, Donate F. Superoxide dismutase 1 (SOD1) is essential for H₂O₂-mediated oxidation and inactivation of phosphatases in growth factor signaling.  Proc Natl Acad Sci USA. 2008;  105 7147-7152
• 52 Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel.  Cancer Cell. 2008;  13 472-482
• 53 Brahimi-Horn M C, Chiche J, Pouyssegur J. Hypoxia signalling controls metabolic demand.  Curr Opin Cell Biol. 2007;  19 223-229
• 54 Warburg O, Posener K, Negelein E. Über den Stoffwechsel der Tumoren.  Biochem Z. 1924;  152 319-344
• 55 Abu-Hamad S, Zaid H, Israelson A, Nahon E, Shoshan-Barmatz V. Hexokinase-I protection against apoptotic cell death is mediated via interaction with the voltage-dependent anion channel-1: mapping the site of binding.  J Biol Chem. 2008;  283 13482-13490
• 56 Goldin N, Arzoine L, Heyfets A, Israelson A, Zaslavsky Z, Bravman T, Bronner V, Notcovich A, Shoshan-Barmatz V, Flescher E. Methyl jasmonate binds to and detaches mitochondria-bound hexokinase.  Oncogene. 2008;  27 4636-4643
• 57 Kitada S, Leone M, Sareth S, Zhai D, Reed J C, Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins.  J Med Chem. 2003;  46 4259-4264